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For a brief period, supplying the data
was enough. More genes meant more
potential drug targets. But now the
victims of the data flood are crying for
help. Companies like Entelos, Inc.
(Menlo Park, California) are coming
to the rescue, by building models that
integrate all those data into a single,
homeostatic, interconnected whole.
The models allow researchers to run
virtual drug trials to determine the
best drug targets, treatment
regimens, and patient populations.
Entelos is approaching the
problem one disease at a time, but
building such models is still “not
trivial,” says Bernhard Palsson, a
modeler from the University of
California, San Diego, who has
founded the company Genomatica to
provide models of single-celled
organisms. “This is not going to be as
easy as people think,” he says. Facing
such a task, it won’t hurt having chief
scientific officer Tom Paterson on
board. As one Entelos employee
notes, “he really is a rocket scientist.”
Rockets, business models, and biology
Paterson’s experience ranges from
aeronautics design to business
strategizing, and Entelos’ modeling
methods are culled from both
worlds. The aerospace industry has
used simulation for years. As in this
industry, Paterson prefers a top-
down approach in which larger
properties are examined first
(Figure 1). “The top-down approach
gives you a context for how the
pieces fit together,” he says. “It
makes you less sensitive to how
much data you have than you would
really think.” 
“Let’s say I start with the basics of
fuel–air mixture and hydraulics, and
eventually work my way up to how an
airplane works,” he continues. “The
amount of detail you need is huge, and
you lack the concept of how the pieces
fit together. So you step back and ask
how the airplane achieves flight. What
are the high level functional properties
that let an airplane do what it does?
Then you work down into the details
until you run out of data.” 
Curing real diseases by creating
virtual diseases.
For the Entelos models, dubbed
PhysioLabs, the first step is to
simulate a healthy version of a
particular corner of physiology.
“Modeling a disease is pretty easy —
there are many ways that you can
build a skyscraper that falls down,”
says Paterson. “A healthy system is a
much tougher design problem.” The
model must simultaneously satisfy
many criteria, with more constraints
being added as the model is refined.
Once again biologists are borrowing
from industry, says Paterson. “There
are a tremendous number of parallels
between air or space vehicles and
biology. Both systems are self-
contained, there are tremendous
numbers of feedback pathways, and
there are tremendous numbers of
concurrent design constraints.”
The constraints make model
building more difficult, but give
researchers more faith in the result.
“It is truly amazing how effective a
mathematically tight model is in
focusing your attention, because you
cannot get away with hand-waving,”
says Entelos CEO Sam Holtzman.
“The math is a very harsh critic.” 
The critic may be arriving just in
time. “It’s become easy for an isolated
biologist to propose a hypothesis that
works in their own small area, but that
doesn’t make sense outside their
area,” says Paterson. The hypotheses
may be falling victim to the simplicity
of cause-and-effect reasoning. “Once
Figure 1
The top level of the Entelos obesity disease
model, as it is depicted on-screen by the
PhysioLab program. Clicking on one of the
bubbles can take the user to the next level of
detail (e.g., to a series of bubbles that
represent all the interconversions that
determine levels of protein storage and
oxidation). At the lower levels, mathematics
and literature references that support each
interconversion are accessed by clicking on
arrows or bubbles. Individual rate constants or
starting values can be changed to modify the
model or to simulate a disease state. When a
disease or treatment simulation is run, many
individual variables can be tracked (see
Figure 2). 
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you start looking at the degree of
feedback, when you ask if it’s cause or
effect, you recognize that it’s both,”
says Paterson. “We encourage our
customers to get away from this idea
of cause and effect. Cause and effect
is like dominoes, and dominoes is the
wrong way to think about disease.”
The models yield some surprising
new properties. “As you put together
a complex system you see principles
emerge that you would not get from a
simpler representation,” says James
Bassingthwaighte (University of
Washington, Seattle). Stuart
Kauffman, now at Bios Group in
Santa Fe, New Mexico, described
such emergent properties in
computer networks, but similar
properties are what make the Entelos
biological models truly useful.
Emergent properties in biological
simulation are perhaps not surprising.
After all, says Bassingthwaighte, “you
can regard life itself as an emergent
property — you get a bunch of
chemicals together and you get life.”
The completed networks also
show robustness — they tend to
return to equilibrium even after
certain parameters are changed.
Theoretically this could make it
difficult to detect errors in the
models, but Adam Arkin of the
University of California at Berkeley
says that “robustness is such a strong
constraint on the model space that it
will be more of a help than a
hindrance.” Because only a few
models will be robust, the property
“reduces the feasible space that you
have to search experimentally.”
The construction process
The biggest challenge in building a
model is converting biology to
mathematics. “There’s no place in
the literature, save for a few systems
like electrophysiology, where you can
actually look up the equations,” says
Paterson. With non-linearity, errors
and different levels of abstraction,
Arkin says that, “the math, I don’t
think, is straightforward. There are
major theoretical holes in simulation
mathematics. There are issues that I
don’t know how they are addressing.”
But Paterson says he can get
significant insights into complex
systems with relatively simple
mathematics, using non-linear
ordinary differential equations.
On another strategy, Arkin says
that Paterson “is absolutely right —
the idea of modeling every atom in
the cell is just stupidity. You have to
go to a higher level.” But, he says,
“you have to choose the higher level
carefully. You have to be very careful
about what you are throwing out.”
To make these decisions for each
new disease, the model builders at
Entelos immerse themselves in the
literature and grill a different panel of
advisers. Inevitably there are conflicts.
In the future, some of these may be
resolved by university researchers
funded by Entelos, although the
company itself has no plans for wet
labs. Individual customers can pick
and choose amongst competing
hypotheses by changing parameters.
So far those customers are large
pharma companies who subscribe to
the PhysioLabs for use in the
discovery phase. Holtzman predicts
that PhysioLabs will be used to help
with clinical trials, and that new
customers may use them after buying
consulting services for a single project.
What is it for?
A particular protein in a model may
be of primary interest only to the one
company that holds the patent
defining that protein as a drug target
(Figure 2). But Holtzman says that
other companies will still have an
interest. “A PhysioLab is a way to
understand your therapeutic targets:
what it is they do; how they achieve
the clinical outcomes,” he says. “You
can look at alternate or combinatorial
therapies, what competitors are
doing, in-licensing opportunities, and
out-licensing opportunities.”
PhysioLabs have been used, for
example, to show that a particular anti-
asthma therapy would have positive
initial effects, but then cause a
disastrous compensatory reaction. An
early version of a PhysioLab (before
Entelos officially existed) was used to
reverse a negative FDA decision, by
showing that some of the phase III
trials of a drug were disappointing
because of an unseen patient bias: the
patients were at university hospitals
and therefore a greater number had a
more serious version of the disease.
Holtzman says the company involved
“had an abundance of data, but no
ability to integrate the data.”
Having it all
Entelos are not the only ones with
grand plans. Bassingthwaighte is an
originator of the Physiome Project —
a loose consortium of researchers who
are simulating the body, one organ
system at a time. Similarly, Physiome,
Inc. (Princeton, New Jersey) has
designed an in silico heart and is
moving on to the immune system.
Modelers feel that their time has
come. “Leaders in the genomics
field are all coming to this realization
that model building is becoming the
rate-limiting step,” says Palsson.
“There’s a major shift taking place in
the biological sciences.” Math is
back, he says, and “biology is going
to become quantitative.”
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Figure 2
An experimental result from the asthma
PhysioLab. Higher anti-IgE dose and longer
anti-IgE treatment both lead to a better result
(higher airway conductance), but it is clear
that the duration of treatment is far more
important than the dose. This should be
taken into account in the design of any trial
with this therapy.
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